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Deficiency of the Mouse Complement Regulatory Protein
mCd59b Results in Spontaneous Hemolytic Anemia with
Platelet Activation and Progressive Male Infertility
al., 1999). Thus, the same MAC that can induce lethal
colloid-osmotic lysis in heterologous cells can also me-
diate physiological and/or pathological signals in autolo-
gous cells (Benzaquen et al., 1994; Nicholson-Weller
and Halperin, 1993). Essential control of the complement
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activation pathways is provided by more than ten plas-Brigham and Women’s Hospital
ma- and membrane-bound inhibitory proteins that re-75 Francis Street
strict complement activation at different stages of theBoston, Massachusetts 02115
system to prevent rapid activation and consumption in2 Harvard Medical School
response to trivial stimuli (Morgan, 1995). In addition toLaboratory for Translational Research
several fluid phase inhibitors, at least three membraneOne Kendall Square
proteins, decay accelerating factor (DAF), membraneBuilding 600, 3rd Floor
cofactor protein (MCP), and complement receptor 1Cambridge, Massachusetts 02139
(CR1), help regulate the C3- and C5-convertases in the
activation pathway, while CD59 restricts MAC formation.
DAF and CD59 are glycan phosphatidylinositol (GPI)-Summary
linked membrane proteins (Davitz et al., 1986; Medof et
al., 1987; Nicholson-Weller et al., 1985) whose relevanceBasal complement activity presents a potential danger
in human physiology is highlighted by paroxysmal noc-for “self” cells that are tightly protected by comple-
turnal hemoglobinuria (PNH). PNH is an acquired hemo-ment regulators including CD59. Mice express two
lytic anemia in which blood cells lack all GPI-anchoredCd59 genes (mCd59a and mCd59b); mCd59b has ap-
proteins, including CD59 and DAF, as a consequenceproximately a 6-fold higher specific activity than
of an acquired somatic mutation of the PIG-A gene inmCd59a. Consistently, mCd59b knockout mice pres-
bone marrow precursors (Parker, 1996; Takeda et al.,ent a strong phenotype characterized by hemolytic
1993; Ueda et al., 1992). Deficiency of these complementanemia with increased reticulocytes, anisopoikilo-
regulatory proteins results in unrestricted autologouscytosis, echinocytosis, schistocytosis, free hemoglo-
MAC formation and thereby in increased intravascularbin in plasma, hemoglobinuria with hemosiderinuria,
hemolysis and activation of platelets with increasedand platelet activation. Remarkably, mCd59b/ males
shedding of platelet microparticles (PMP), respectivelyexpress a progressive loss of fertility associated with
responsible for the anemia and serious thrombotic com-immobile dysmorphic and fewer sperm cells after 5
plications suffered by PNH patients.months of age. This work indicates that mCd59b is a
Despite strong evidence for a key role of CD59 inkey complement regulator in mice and that CD59 is
restricting complement activation and MAC formationcritical in protecting self cells; it also provides a novel
on autologous cells (Fisicaro et al., 2000), an mCd59amodel to study complement regulation in human dis-
knockout mouse (Holt et al., 2001) and an mCd59a andeases.
DAF double-knockout mouse (Miwa et al., 2002) exhib-
ited some intravascular hemolysis, as evidenced by in-Introduction
creased free hemoglobin in plasma, but were not ane-
mic. A possible explanation for the lack of overtThe complement system is an effector of the immune
hemolytic anemia in these mice can be found in the
system; it consists of a group of more than 12 soluble
discovery that mice have a second mCd59 gene (termed
proteins that interact with one another in three distinct
mCd59b) (Qian et al., 2000) that is expressed in most
enzymatic activation cascades known as the classical, tissues (Qin et al., 2001). We have functionally character-
alternative, and lectin pathways. All activation pathways ized mCd59b and shown that mCd59b has an approxi-
converge at the level of C3. Thereafter, they share a mately 6-fold higher specific activity as an inhibitor of
common sequence through the late components C5, C6, MAC formation than mCd59a (Qian et al., 2000; Qin et
C7, C8, and C9. C9 polymerizes to form the membrane al., 2001). These findings prompted us to study the func-
attack complex (MAC), a heteropolymeric complex with tion of mCd59b in vivo. Herein, we report that the tar-
the capacity to insert into cell membranes and to form geted deletion of mCd59b has produced mice with a
a trans-membrane pore of 7–9 nm internal radius strong phenotype characterized by spontaneous hemo-
(Mayer, 1984). Diffusion of ions and water through the lytic anemia with hemoglobinuria and hemosiderinuria,
MAC pore can lead to colloid-osmotic swelling and lysis significant reticulocytosis, and intravascular platelet ac-
of the target cell. The MAC pore can also open tran- tivation comparable to the hemolytic anemia seen in
siently, generating significant but non-lytic changes in patients with PNH (for this reason we also call these
the cell membrane permeability, and release of some features in mCd59b/ mice a PNH-like phenotype). In
intracellular cytokines of molecular weight 20–30 kd addition, mCd59b/, which initially are normally fertile,
such as bFGF or IL-1 (Acosta et al., 1996; Benzaquen progressively lose their fertility; this acquired infertility
et al., 1994; Halperin et al., 1993a, 1993b; Shankland et is associated with intriguing sperm cell abnormalities
including decreased number, abnormal shape, and loss
of mobility. Together, the hemolytic anemia and the ac-*Correspondence: jose_halperin@hms.harvard.edu
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Figure 1. Targeted Disruption of mCd59b
(A) Targeting vector constructed to replace exon 3 of mCd59b by Neo. TK was inserted at the 5 end of the homologous region. Double-
headed arrows indicate the size of the fragments seen in Southern blot analysis of wild-type (top) and targeted (bottom) alleles after the
external probe (red box) hybridized to the HindIII digestion of genomic DNA. Primer P2 from the Neo gene and Primer P4 from the external
region of the 3 end of the homologous region were used for PCR amplification of the 4 kb expected fragment from the genomic DNA of the
targeted stem cell lines.
(B) Southern analysis with the external probe to determine homologous recombination of left arm. The 20 kb and 15 kb HindIII bands represent
the wild-type and the targeted fragments, respectively.
(C) mCd59b/ mice genotyping by PCR. Top: PCR amplification of the wild-type fragment (expected 1.1 kb fragment from mCd59a region,
and 500 bp from mCd59b region with the primer pair P1 and P3). Bottom: PCR amplification of the targeted fragment (expected 500 bp from
target allele) with the primer pair P2 and P3. L1, 1 kb ladder; L2, 100 bp ladder; and N, negative (no template) control.
(D) Top: Northern blot analysis of total RNA in testes from either mCd59b/ or mCd59b/. The 0.5 kb and truncated mRNA were respectively
detected in mCd59b/ and mCd59b/ testes with the specific probe for mCd59b/ exon 4. Bottom: total RNA loading.
(E) RT-PCR analysis with the specific primer from either exon 2 or exon 4 of mCd59b. 1, 100 bp ladder; 2, no template; 3, mCd59b cDNA
plasmid; 4, mCd59a cDNA plasmid; 5, mCd59b/ testis; 6, mCd59b/ kidney; 7, mCd59b/ testis; and 8, mCd59b/ kidney.
(F) mCd59b/ (left panel) or mCd59b/ (right panel) RBC stained with either anti-mCd59a (blue) or mCd59b (green) specific antibodies.
Negative controls (black and red) represent staining with pre-immune sera from the same rabbits in which the respective antibodies were
raised.
quired reproductive problems observed in mCd59b/ resulted in mCd59/ mice (Figure 1B). Intercrossing
mCd59/ males and females generated mCd59b/,confirm the key role played by CD59 as a physiologically
relevant inhibitor of complement activation and provide mCd59b/, and mCd59b/ offspring in the expected
Mendelian ratios (Figure 1C). The successful disruptiona much-needed model to study complement and com-
plement regulatory proteins in reproduction as well as of the mCd59b gene was confirmed by Northern analysis
of the testis where mCd59b is highly expressed.in the pathogenesis of a variety of diseases in which
disregulation of complement has long been suspected. mCd59b/ testes expressed a truncated form of
mCd59b mRNA, which was readily detected by Northern
analysis with an mCd59b exon 4-specific probe (FigureResults
1D). Unambiguous confirmation of the successful dele-
tion of exon 3 in mCd59b/ was obtained by RT-PCRGeneration of mCd59b Knockout
analysis of renal and testicular samples followed by se-Mouse (mCd59b/)
quencing of the RT-PCR product. Using mCd59b exonmCd59b/ was generated disrupting the mCd59b gene
2- and exon 4-specific primers, we detected a 317 bpby homologous recombination in ES cells. Figure 1A
product in both testicular and renal samples fromshows the targeting vector designed to delete exon 3
mCd59b/. In contrast, the same primers amplified aof mCd59b, which encodes for the major functional pep-
tide of mCd59b. Crossing chimeric mice with C57BL/6 shorter, 215 bp long product in the testis of mCd59b/
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Table 1. Key Hematological Parameters in mCd59b/, mCd59b/, and mCd59b/
Hb (g/dl) RBC (1012/L) HCT (%) RDW (%) Retic (%) WBC (109/L) Plts (109/L)
mCd59b/ 11.2  2a 6.51  1.12a 34.5  4.2a 16  0.6a 9.5  4a 4  1.5 1099  300
mCd59b/ 14.2  0.6 9.20  0.64 46.5  1.9 12.6  0.5 2.9  0.6 4.50  2 1202  430
mCd59b/ 14.6  0.3 9.30  0.50 45.1  2.5 12.0  0.3 2.5  1.0 4.66  1 1144  245
Hb, hemoglobin; RBC, red blood cell count; HCT, hematocrit; RDW, RBC distribution width; Retic, reticulocytes; WBC, white blood cell count;
Plts, platelets. Mean  SD of six mice per group (three males and three females).
a p  0.01 comparing mCd59b/ against either mCd59b/ or mCd59b/.
(but not in the kidneys) (Figure 1E). Sequencing of RT- seen in mCd59b/ but not in mCd59b/ mice (Figure
3G). Together, these findings underscore the key physio-PCR products from the testis of mCd59b/ verified that
the 102 bp exon 3 that encodes for 34 amino acids in logical role of CD59 in general and of mCd59b in particu-
lar in protecting cells from complement-mediated dam-mCd59b was successfully deleted in mCd59b/ mice.
At the protein level, FACS analysis of RBC using age in the absence of activating stimuli.
mCd59a- or mCd59b-specific antibodies detected both
mCd59a and mCd59b in mCd59b/ mice (Figure 1F, Increased Complement Sensitivity in RBC
left). In contrast, mCd59b/ RBC only expressed mCd59a of mCd59b/
(blue curve) but not mCd59b (green curve) (Figure 1F, mCd59b/ RBC have a significantly higher sensitivity
right). Negative controls (black and red curves in Figure to complement-mediated lysis than mCd59b/ RBC.
1F) were obtained with pre-immune sera from the same This was demonstrated using four different methods of
rabbits in which the respective antibodies were raised. complement activation and rat serum as the source of
complement: (1) The acidified serum Ham’s test, the
clinical standard for the diagnosis of PNH in humans,mCd59b/ Mice Exhibit Hemolytic Anemia
measures complement-mediated hemolysis via the al-with Spontaneous Platelet Activation
ternative pathway. Figure 4A shows the increased he-Complement-mediated hemolytic anemia and thrombo-
molysis of mCd59b/ as compared with mCd59b/ orsis due to absence of the GPI-linked complement regu-
mCd59b/ RBC when exposed to acidified serum. (2)latory proteins in blood cells are the predominant clinical
Cobra venom factor (CVF) is a powerful activator of thefeatures of PNH. Remarkably, mCd59b/ mice exhibit
alternative complement pathway because it carries ahematological abnormalities similar to those seen in hu-
functional homolog of C3b that amplifies the alternativeman PNH.
complement cascade. mCd59b/ RBC exposed to se-Spontaneous Hemolytic Anemia
rum and CVF exhibited a significantly higher hemolysisEvidence for hemolytic anemia in mCd59b/ mice is
than either mCd59b/ or mCd59b/ RBC (Figure 4B).provided by significantly low RBC counts, hemoglobin
(3) The classical pathway of complement is activatedconcentration, and hematocrit, as well as significantly
by antigen-bound antibodies that expose a binding siteincreased reticulocyte counts (Table 1), free hemoglobin
for C1q in their Fc region. mCd59b/ RBC sensitizedin plasma (Figure 2A), hemoglobinuria (Figure 2B), the
with anti-RBC antibodies and then exposed to serumpresence of hemosiderinuria (Figure 2C), as well as ab-
as source of complement showed a much higher sensi-normal cell morphologies (Figures 2F–2L). Figures 2F–2L
tivity to complement-mediated lysis than mCd59b/ orshow the remarkable morphological changes observed
mCd59b/ RBC (Figure 4C). (4) Terminal complementin blood smears of mCd59b/ mice that include aniso-
components C5b through 9 assemble in a sequentialpoikilocytosis, reticulocytosis (Figures 2F–2J), echino-
manner to form the MAC. Antibody-sensitized RBC werecytosis (Figures 2F–2J), schistocytosis (Figures 2F and
exposed to C8-deficient serum to form RBC-C5b-7 cells.2G), and circulating erythroblasts (Figures 2H and 2I),
When the mCd59b/ RBC-C5b-7 cells were incubatedthe characteristic RBC abnormalities seen in human he-
with rat serum-EDTA as a source of C8 and C9 to formmolytic anemias (Roitt et al., 2001). The presence of
the MAC, they exhibited a much higher lysis than eitherRBC fragments and echinocytes in mCd59b/ mice
mCd59b/ RBC-C5b-7 or mCd59b/ RBC-C5b-7 cellswas confirmed by electro-microscopy (Figure 2L).
(Figure 4D). That the hemolysis seen in all four assaysPlatelet Activation
was mediated by complement was confirmed by usingThrombosis in PNH is due to complement-mediated
heat-inactivated serum (56C for 30 min) as a negativeplatelet activation (Wiedmer et al., 1993). Evidence for
control (data not shown).platelet activation in mCd59b/ mice is provided by an
8-fold increased number of PMP documented by FACS
analysis (Figures 3A–3F), as well as by transmission mCd59b Is More Active Against Mouse Complement
Than mCd59aelectron microscopy (Figures 3G–3I). PMP are shed off
activated platelets and express pro-thrombotic mole- Northern blot analysis of brain, liver, kidney, and testis
with an mCd59a-specific probe showed that there is nocules on their surface (Hugel et al., 1999; Wiedmer et
al., 1993). The electron microscopy pictures in Figures upregulation of mCd59a in mCd59b/ mice at mRNA
level, as documented by Figure 5A. Using mCd59a and3H and 3I show the ultrastructure of platelets spreading
with long and stubby filopodia, some containing bundles mCd59b transfected CHO cells exposed to human com-
plement and the dye-release assay, we have shownof long filaments, and platelet aggregates, all character-
istic features of activated platelets (Stenberg et al., 1998) previously that mCd59b has an approximately 6-fold
Immunity
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Figure 2. Free Hemoglobin in Plasma, Hemoglobinuria, and Hemosiderinuria in mCd59b/ Mice and Morphological Abnormalities in
mCd59b/ RBC
Significantly increased free hemoglobin in mouse plasma determined spectroscopically at 540 nm compared to either mCd59b/ or mCd59b/
(n  12 for each group comprised of six males and six females, p  0.01) (A) and significantly increased hemoglobinuria determined at 414
nm (p  0.01) in mCd59b/ mice compared to either mCd59b/ or mCd59b/ mice (n  6 for each group comprised of three males and
three females, p  0.01) (B). Hemosiderine staining (blue) in mCd59b/ urine (C) and not in mCd59b/ urine (D). mCd59b/ control blood
smear (E) and mCd59b/ blood smears (F–J) showing anisopoikilocytosis and increased reticulocytes (F–J), echinocytes (F–J), schistocytes
(F and G), and the presence of circulating erythroblasts (H and I, black arrow). In (K) and (L), electro-microscopy views of mCd59b/ (K) and
mCd59b/ RBC (L), the latter showing abnormal morphology and budding in some RBC (red arrows).
higher specific activity than mCd59a (Qin et al., 2001). mCd59b/ Males Progressively Lose Fertility
Wild-type mice remain normally fertile for approximatelyThis result was confirmed in a hemolytic assay in which
rabbit RBC were exposed to mouse serum (as a source 2 years (Wirth-Dzieciolowska and Czuminska, 2000). Re-
markably, mCd59b/ males are normally fertile until ap-of complement) in the presence or absence of purified
mCd59a or mCd59b (van Dijk et al., 1980). At least ten proximately 5 months of age when they start to progres-
sively lose fertility and eventually become infertile.times more mCd59a than mCd59b was required to
achieve a comparable level of rabbit RBC protection Infertility was defined by the failure to impregnate young
mCd59b/ females after three consecutive matings;against mouse complement (data not shown). Together,
these results clearly indicate that mCd59b is a much each male was mated against three different mCd59b/
females. By 8 months of age, only 20% of the males arestronger inhibitor of mouse MAC formation than
mCd59a. This interpretation was confirmed comparing still fertile but generate a significantly smaller litter size
of no more than two pups per wild-type female (Figurethe sensitivity to complement-mediated lysis of RBC
from mCd59a/ (kindly provided to us by Dr. P. Morgan), 6A). In addition, mCd59b/ males display normal sexual
behavior toward females and generate copulation plugsand from mCd59b/ mice, in both cases exposed to
mouse complement (Figures 5B and 5C). mCd59b/ independently of their age.
This progressive loss of fertility in mCd59b/ malesRBC were much more sensitive to lysis by mouse com-
plement than mCd59a/ RBC. These results indicate is due to immobile, dysmorphic, and fewer sperm cells
(Figures 6B–6E). Figures 6B and 6C show still framesthat mCd59b confers mouse RBC significantly more pro-
tection against mouse complement than mCd59a; they from video pictures obtained from either mCd59b/ (B)
or mCd59b/ (C) (actual motion pictures can be seenalso explain the much stronger hemolytic phenotype
expressed by mCd59b/ mice as compared with at http://134.174.152.43/videos.html). The video picture
shows that all sperm cells from mCd59b/ mice weremCd59a/ mice.
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Figure 3. FACS Analysis of Platelet-Poor Plasma with Anti-Glycoprotein IIb Monoclonal Antibodies Shows Increased Platelet Microparticles
in mCd59b/ Mice
(A) mCd59b/ PRP without antibody staining.
(B) mCd59b/ PRP stained with anti-glycoprotein IIb mAb.
(C) PRP from mCd59b/ stained with anti-glycoprotein IIb mAb. The events shown in the upper-right quadrants of (B) and (C) are platelets.
Platelet count in PPP using laser technology CBC counting confirmed the absence of platelets.
(D) mCd59b/ PPP without antibody staining.
(E) mCd59b/ PPP stained with anti-glycoprotein IIb mAb.
(F) mCd59b/ PPP stained with anti-glycoprotein IIb mAb. The events of the upper-right quadrant in (E) and (F) represent PMP. PMP in (F)
are 8 times higher than in (E).
(G–I) Electro-microscopy photographs showing the formation of stubby and elongated filopodia and platelet aggregation in mCd59b/ (H
and I) but not in mCd59b/ (G).
mobile (B), whereas almost all sperm cells from infertile sis and bone marrow stress. We also documented mor-
phological changes in platelets with formation of plateletmCd59b/ males were immobile (C). In some instances,
one or two sperm cells showed contraction-like move- aggregates and PMP, all indicative of spontaneous
platelet activation. These findings are very similar to thements without displacement.
The sperm smears made from either infertile characteristic hematologic features of human PNH, a
clonal acquired bone-marrow stem-cell disorder thatmCd59b/ or age-matched mCd59b/ males stained
with cresyl violet showed that there is a substantial de- results in the lack of GPI-anchored proteins including
the complement inhibitors DAF and CD59 in the cell-crease in the number of spermatozoids in infertile
mCd59b/ males (Figure 6E). In addition, the histology surface of blood cells (Takeda et al., 1993). Deficiency of
complement regulatory proteins in blood cell membranesshowed loss of spermatozoid’s head and multinucleated
cells with increased cytoplasm (E) compared with those breaks the delicate balance between complement activa-
tion and restriction, resulting in complement-mediated he-in mCd59b/ male (D).
molysis and thrombosis (Parker, 1996). Similar RBC ab-
normalities are also seen in diseases characterized byDiscussion
increased complement activation such as immune hemo-
lytic anemia in which autoantibodies against epitopes inThis work demonstrates that the targeted deletion of
mCd59b results in spontaneous hemolytic anemia with RBC activate complement and increase MAC-mediated
hemolysis. Comparable abnormal RBC morphologies,hemoglobinuria and hemosiderinuria, reticulocytosis,
circulating erithroblasts, and a variety of morphological particularly echinocytes like those shown in Figures 2F–
2J, can be seen after in vitro exposure of RBC to eitherabnormalities in RBC indicative of intracellular hemoly-
Immunity
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Figure 4. mCd59b/ RBC Are More Sensitive to Complement-Induced Lysis
Four lytic assays were used to test lytic susceptibility of mCd59b/ erythrocytes. (A) Ham’s test. (B) CVF-triggered reactive RBC lysis. (C)
Classical pathway assay in antibody-sensitized RBC exposed to rat serum. (D) C5b-7 site assay. RBC bearing preformed C5b-7 sites were
incubated with dilutions of rat serum (mCd59b/, red; mCd59b/, blue; and mCd59b/, black). Results are mean  SD of three mice per
group.
activated complement or purified MAC (Roitt et al., (Figure 3), which defines these microparticles as plate-
let-derived or PMP. It has been shown that MAC acti-2001).
mCd59b/ but neither mCd59b/ nor mCd59b/ vates platelets and that MAC-activated platelets expose
on their surface coagulation factor Va binding sites andmice exhibit an increased number of microparticles
bearing the platelet-specific marker glycoprotein IIb have increased prothrombinase activity, and also shed
Figure 5. mCd59b Is More Active against Mouse Complement Than mCd59a
(A) Top: Northern analysis of mCd59a mRNA expression in the multiple tissues (T, Testes; K, Kidney; L, Liver; and B, Brain) from either
mCd59b/ or mCd59b/ with the specific probe to mCd59a. Bottom: total RNA loading.
(B) CVF-triggered alternative pathway assay in mCd59a/ and mCd59b/ RBC exposed to mouse complement (results are mean  SD of
three mice per group).
(C) Classical pathway assay in antibody-sensitized mCd59a/ and mCd59b/ RBC exposed to mouse complement (results are mean  SD
of three mice per group).
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Figure 6. Progressive Loss of Fertility in mCd59b/ Males
(A) The curve for the loss of fertility in mCd59b/ males.
(B and C) Loss of motility in infertile mCd59b/ male sperm. (B) mCd59b/ males; (C) mCd59b/ males (video pictures can be seen at:
http://134.174.152.43/videos.html; video clip 1  mCd59b/; video clip 2  mCd59b/; and video clip 3  mCd59b/).
(D and E) Cresyl violet-stained sperm smears. (D) mCd59b/; (E) mCd59b/.
off pro-coagulant PMP enriched in factor V receptors. ously damage “self” cells. It also illustrates that CD59
plays a critical physiological role in protecting circulat-Since the clonal defect in PNH also makes platelets
deficient in complement/MAC membrane inhibitors, ing cells against complement-mediated self damage.
Several lines of evidence indicate that CD59 is thePNH platelets are more susceptible to complement at-
tack (Wiedmer et al., 1993) and PNH patients express most relevant complement regulatory protein in humans
(Fisicaro et al., 2000). An isolated deficiency of DAFa high number of circulating pro-coagulant PMP (Gral-
nick et al., 1995; Hugel et al., 1999) and experience a has been described in four human families that had an
unusual blood group phenotype termed Inab (Lin et al.,high incidence of thrombotic events that is the leading
cause of morbidity and mortality in PNH. It will be of 1988; Telen and Green, 1989). None of the proposita
had symptoms suggestive of PNH, although DAF wasgreat interest to determine if an increased incidence of
thrombosis is another phenotypic characteristic of the totally absent on all circulating cells (Reid et al., 1991).
In contrast, an index case from Japan described a manmCd59b/ mice.
The phenotype of the mCd59b/mice described here who had a global deficiency of CD59 due to a single
nucleotide deletion in the CD59 gene. This subject ex-indicates that the complement system turns over at a
basal rate that, in the absence of regulators, can seri- pressed a severe PNH-like phenotype from the age of
Immunity
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13 and also had a stroke that left him with permanent crossing mCd59b/ with C3/ mice, an experiment cur-
neurological damage (Yamashina et al., 1990). Consis- rently in progress in our laboratory.
tent with the human data, DAF knockout (Sun et al., Our results document that mCd59b is critical in pro-
1999) mice do not exhibit the spontaneous hemolytic tecting mouse circulating cells and probably sperm cells
phenotype that is present in mCd59b/. It was surpris- from the basal “tickover” complement attack. Whether
ing, however, that both the mCd59a/ mouse (Holt et other tissues are also affected when the delicate balance
al., 2001) and the mCd59a//DAF/ double-knockout between complement activity and regulation is broken
(Miwa et al., 2002) presented increased free hemoglobin by the functional abrogation of mCd59 is currently under
in plasma indicative of intravascular hemolysis but no active investigation. This is of interest because we have
anemia. This absence of the expected hemolytic anemia shown and others have confirmed that insertion of the
was attributed to the presence of Crry, an analog of DAF MAC into endothelial cell membranes results in the re-
and MCP that inhibits early complement activation and lease of an array of growth factors and cytokines that
is only expressed in mice and rats (Kim et al., 1995). auto- and paracrinically stimulate cell proliferation
The results presented here now demonstrate that the (Acosta et al., 1996; Benzaquen et al., 1994; Couser,
functional deletion of mCd59b is sufficient to create an 1998; Kilgore et al., 1997; Torbohm et al., 1990; Torzew-
intense hemolytic anemia and platelet activation that ski et al., 1996). These findings led us to propose that
mimic most hematological features of the human PNH functional abrogation of CD59 in tissues other than blood
disease. The data also indicate that (1) mCd59b is a more cells could locally increase complement sensitivity and
potent physiological inhibitor of mouse MAC formation provide a pathogenic mechanism for the development of
than mCd59a, as predicted from its higher specific activ- chronic proliferative diseases. The mCd59b/ mouse
ity we have reported previously (Qin et al., 2001) and reported here represents a useful model to test this
confirmed here by showing that mCd59b/ RBC are hypothesis as well as to develop different animal models
much more sensitive to mouse complement than of proliferative, inflammatory, or degenerative human
mC59a/ RBC (Figures 5B and 5C), and (2) in mice as diseases in which a pathogenic role of complement has
well as in humans, CD59 is more physiologically relevant long been suspected, including atherosclerosis, arthri-
than DAF as a protector against “self” damage by basal tis, and Alzheimer’s disease (Seifert and Kazatchkine,
complement activity. Regarding the mouse- and rat- 1988; Shen et al., 1995; Yang et al., 2000).
specific Crry protein, it is possible that the relative roles Specifically, recent work from our laboratory has
of the different complement regulatory proteins such as shown that human CD59 is inhibited by glycation, the
Crry and CD59 in protecting self cells from complement nonenzymatic attachment of glucose to amino groups
attack would shift depending on the tissue/site of com- in proteins that occurs in diabetes mellitus as a conse-
plement attack (Matsuo et al., 1994; Mizuno et al., 1997), quence of hyperglycemia (Acosta et al., 2000). Glyca-
as well as on the mechanism and/or level of activation. tion-inactivation of human CD59 is due to a glycation
For example, Crry seems to be critical during early fetal motif formed by amino acid residues K41-H44 that is
development since Crry/ mice were non-viable be- present in human CD59 but not in CD59 from mice or
yond 9 days of pregnancy due to maternal complement any other species (Acosta et al., 2000; Bodian et al.,
attack on the placenta (Xu et al., 2000). In contrast, 1997). This observation led us to propose that glycation-
mCd59b seems to be relevant for protection of RBC and inactivation of human CD59 could provide an explana-
platelets as well as sperm cells. tion for the unique propensity of humans to develop
A role of CD59 in protecting human sperm from com- vascular proliferative diabetic complications. Because
plement attack has long been suspected. Indeed, CD59 mouse Cd59 is not susceptible to glycation-inactivation,
of a molecular weight identical to that on other cells is a mouse model to test this hypothesis required the func-
highly expressed on human sperm and can protect tional deletion of mCd59, as we have now achieved
sperm from the damaging effects of complement. Also,
in mCd59b/. It will be therefore of great interest to
CD59 is present in a GPI-anchored, prostasome-associ-
determine if diabetic mCd59b/ mice develop the mi-
ated form in cell-free seminal plasma. Binding of prosta-
cro- and/or macrovascular disease comparable to thatsome to sperm can “deliver” CD59 to the cell surface,
seen in complicated human diabetes.thereby increasing protection of sperm from comple-
In summary, the successful functional deletion ofment attack (Rooney et al., 1993). Incubation of sperm
mCd59b and the resulting abnormal phenotype demon-with neutralizing anti-CD59 antibodies and human se-
strate that mCd59b is a key physiological inhibitor ofrum results in sperm immobilization and lysis, whereas
MAC formation in mice and imply that the mCd59b/sperm with functional CD59 are protected (Rooney et
subject of this report may represent a needed animalal., 1992). We have shown that mCd59b is highly ex-
model to help better understand the biological functionspressed in mouse testis (Qian et al., 2000; Qin et al.,
of CD59, explore the potential pathogenic role of com-2001). The progressive loss of fertility due to striking
plement in a variety of diseases under different stres-sperm abnormalities in mCd59b/ strongly indicates
sors, and test novel therapeutic strategies for those con-that mCd59b protects sperm cells from autologous
ditions.complement attack, although another functional role of
mCd59b in reproduction cannot be conclusively ruled
Experimental Proceduresout at this time. The progressive nature of the infertility
is consistent with the known age-dependent increase Generation of mCd59b-Deficient Mice
in mouse complement activity (Fukuoka et al., 1982). The mCd59b gene spans 4 exons with the region coding the func-
Final proof that the observed sperm damage and infertil- tional peptide in exons 3 and 4 (Qin et al., 2001). A bacterial artificial
chromosome (BAC) that covers the mCd59 genes was used to am-ity in mCd59b/ is mediated by complement will require
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plify the two regions on either side of exon 3 of mCd59b by PCR. platelets and PMP was performed using a rat monoclonal IgG1
antibody against mouse platelets expressing the integrin IIb cou-For homologous recombination, the two3.5 kb flanking fragments
were subcloned into a vector on either side of the neomycin resis- pled to FITC (sc-19963 FITC, Santa Cruz Biotechnology, Santa Cruz,
California) (Forlow et al., 2000; Heijnen et al., 1999). For transmission,tance gene (Neo, from pKO Scrambler NTKV-1906; Strategene, La
Jolla, California), forming a 7 kb homologous sequence gene-target electro-microscopy blood was drawn by heart puncture directly into
Karnovsky’s fixative and processed as in Vyas et al. (1999).construct capable of replacing Neo for exon 3 (Figure 1A). To enable
negative selection against random integration, the thymidine kinase
gene from the herpes simplex virus was also included at the 5 end In Vitro Complement-Mediated Assays on Mouse Erythrocytes
of the construct. Sensitivity of mouse RBC to either rat or mouse complement-medi-
Embryonic stem cells derived from 129/Sv mice were transfected ated attack was assessed by four different methods: (1) acidified
with the linearized vector by electroporation, and G418-resistant serum lysis assay (Ham’s test) (Ham, 1937); (2) Cobra venom factor
clones were screened for homologous recombination by Southern lysis assay; (3) antibody-sensitized RBC method; and (4) MAC-for-
blot analysis with the external left-arm probe shown in Figure 1B, mation by C5b-7 site assay, all as described in Holt et al. (2001). In
and by PCR with the right-arm P1 and P4 primers from the Neo all cases, hemoglobin in the supernatant of lysed RBC was deter-
gene and the external region at the 3 end, respectively (data not mined by the absorbance at 414 nm, and percent lysis was calcu-
shown). Two independent cell lines with targeted deletion of lated as: % lysis  (test OD414  blank OD414 / total lysis OD414 
mCd59b (ES2 and ES4; Figure 1B) were separately microinjected blank OD414) 	 100.
into C57BL/6 blastocysts. Chimeric males were crossed with female
C57BL/6, and germline transmission was detected by the presence Confirmation of the Higher Functional Activity of mCd59b
of agouti-colored offspring. mCd59a-Flag-tagged and mCd59b-Flag-tagged protein were ex-
mCd59b/ were identified by Southern blot analysis and inter- pressed in CHO cells and purified from CHO cells with anti-Flag
crossed to produce mCd59b/, mCd59b/, and mCd59b/ lit- antibody (Qian et al., 2000; Qin et al., 2001), and their activity was
termates. For genotyping by PCR, we used the primer pair P1 and P3 measured in a hemolytic assay using rabbit RBC, human C5b-6 and
to amplify the corresponding fragment in the wild-type chromosome C7 plus mouse serum-EDTA (40 mM) diluted 1:800 as the source
and the primer pair P2 and P3 to amplify the corresponding fragment of mouse C8 and C9 (van Dijk et al., 1980) (Acosta et al., 2000). The
in the targeted chromosome (Figure 1C). amount of protein was determined by Western blot with anti-Flag
antibody.
Northern Blot Analysis, RT-PCR Analysis,
and RT-PCR Sequencing Sperm Analysis
Total RNA from the testes of mCd59b/ and mCd59b/ were iso- mCd59b/ males and age-matched wild-type controls of the same
lated using the trizol reagent and hybridized with the 32P-labeled genetic background were euthanized, and their sperm cells were
mCd59b specific probe from mCd59b exon 4, as described (Qin et recovered from the epididymis and placed in 500 
l pregassed
al., 2001). RT-PCR was performed with the following primers: for- Whittingham’s medium plus 30 mg/ml BSA, as described inFraser
ward, 5 GAGGGGACTCATCTTACTCC 3 (specific to mCd59b exon and Drury (1975). Sperm mobility under light microscopy was re-
2) and reverse, 5 AATGAGGAAGTTTCTGCGTTG 3 (specific to corded with a video camera. The sperm smears made from infertile
mCd59b exon 4) (Qin et al., 2001). The reverse primer was used and age-matched wild-type males were stained with cresyl violet.
for sequencing RT-PCR product (Tufts University Core Sequencing
Facility, Boston, Massachusetts). Acknowledgments
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